Form 4: Director Alessandro Riva Receives Century Therapeutics Grant

Director Alessandro Riva was granted 74,000 stock options in Century Therapeutics, Inc. (IPSC) on June 11, 2026.

Summary

• Alessandro Riva, a Director at Century Therapeutics, Inc., was granted 74,000 stock options.
• The options have an exercise price of $2.24 per share.
• The grant date for these options is June 11, 2026.
• The options are set to expire on June 11, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of these options.

Risks

• The value of the options is dependent on the future market performance of IPSC common stock.

Future Outlook

The options vest on the earlier of June 11, 2027, or the next annual meeting of stockholders, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to incentivize long-term strategic oversight and retention of board members.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is consistent with standard corporate governance practices for mid-cap biotechnology firms.
• Vesting schedules tied to annual meetings are common practice to ensure board continuity.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on June 11, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

Century Therapeutics, IPSC, Form 4, Insider Trading, Stock Options, Director Compensation